References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2017-4-52-62

medsovet-1852

Research Article

Социально значимые инфекции

Socially significant infections

ИНГИБИТОРЫ ИНТЕГРАЗЫ ВИЧ — ОСНОВА ЭФФЕКТИВНОЙ И БЕЗОПАСНОЙ АНТИРЕТРОВИРУСНОЙ ТЕРАПИИ

HIV INTEGRASE INHIBITORS: THE BASIS OF EFFECTIVE AND SAFE ANTIRETROVIRAL THERAPY

ШАХГИЛЬДЯН

В. И.

SHAKHGILDYAN

V. I.

к.м.н.

PhD in Medicine

Центральный научно-исследовательский институт эпидемиологии РоспотребнадзораРоссияCentral Research Institute of Epidemiology of RospotrebnadzorRussian Federation

2017

26052017

045262

2017

ШАХГИЛЬДЯН В.И.

SHAKHGILDYAN V.I.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/1852

В статье рассматриваются вопросы эффективности и безопасности ингибиторов интегразы ВИЧ (ралтегравира, долутегравира) в схемах антиретровирусной терапии (АРВТ) у больных ВИЧ-инфекцией различных групп: с высокой концентрацией РНК ВИЧ в крови, низким количеством CD4-лимфоцитов в крови, беременных, при сочетании ВИЧ-инфекции с туберкулезом или хроническим гепатитом С, больных старшего возраста и/или с высоким кардиоваскулярным риском, нейрокогнитивными расстройствами. Особое внимание уделяется минимальному риску развития поздних осложнений АРВТ при использовании в схемах АРВТ ралтегравира и возможности сочетания ралтегравира с лекарственными препаратами различных классов.

The article examines the efficacy and safety of HIV integrase inhibitors (raltegravir, dolutegravir) in antiretroviral therapy (ART) regimens in various groups of HIV-infected patients: patients with high HIV RNA blood levels, patients with low CD4-lymphocytes blood count, pregnant women, patients with tuberculosis or chronic hepatitis C, and patients in later years and /or with high cardiovascular risk, neurocognitive disorders. Particular attention is paid to the minimal risk of developing delayed ART complications in using raltegravir in ART regimens and combining raltegravir and drugs of various classes.

ингибиторы интегразы ВИЧралтегравирбезопасность АРВТ

HIV integrase inhibitorsraltegravirART safety.

References1

Покровская А.В., Ладная Н.Н., Юрин О.Г., Дементьева Л.А., Покровский В.В. Каскадная модель в оценке эффективности организации медицинской помощи ВИЧ- позитивным лицам. Эпидемиология и инфекционные болезни. Актуальные вопросы, 2015, 1: 15-18.

Лиознов Д.А. Инфекционные болезни: проблемы, достижения и перспективы. Санкт-Петербург, 1-2 декабря 2011. health.elsevier.ru/attachments/editor/file/115/1_M_2_5.pdf.

Survey on Treatment Adherence by HIV+ People. Savitz Research, September 2000. (Sponsored by GlaxoSmithKline).

BASELINE (2013), InvolvementofpeoplelivingwithHIVintheircar e: Surveyhttp://static.squarespace.com/static/5152d54fe4b0b3e0d1106165/t/5209dd21e4b0 f89d3273bdcd/1376378145610/Survey_Results_2013.pdf.

Канестри В.Г. Безопасность и переносимость современных схем антиретровирусной терапии у взрослых больных ВИЧ-инфекцией. Автореф. Дис. … д-ра мед наук. М., 2014.

Patients Spurn AIDS Drugs Due to Side Effects Aug 6, 2008 By: George Koroneos, Online Content & News Editor PharmExec Direct.

ATLISInternationalSurvey2010http://www.iapac.org/ATLIS/ATLIS2010/Fact%20Sheet%20Ke y%20Regional%20Findings%20with%20Stigma%20FINAL.pdf.

Шахгильдян В.И., Беляева В.В. Паллиативная помощь больным ВИЧ-инфекцией.Глава в ВИЧ-инфекция и СПИД»: национальное руководство. Под ред В.В. Покровского. М.: ГЭОТАР-Медиа, 2013: 391-413.

Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe(Version 8.1, October, 2016). European AIDS Clinical Society (http://www.eacsociety.org).

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) July 14, 2016 (http://aidsinfo.nih.gov).

Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. 2016 Recommendations of the InternationalAntiviral Society–USA Panel. JAMA, 2016, 316(2): 191-210. doi: 10.1001/jama.2016.8900.

Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV-infection: recommendations for a public health approach — 2nd edition, WHO, 2016. 13.Hoffmann С, Rockstroh JK. HIV 2015/2016 www.hivbook.com. Hamburg: Medizin Fokus Verlag, 2015. С. 756.

Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr, 2013 May 1, 63(1): 77-85. Available at http: //www.ncbi.nlm.nih.gov/pubmed/23412015.

Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses M-A, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K. Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy–Naive Patients: Week 96 and Week 144 Results from the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr, 2015 Dec 15, 70(5): 515-9. doi: 10.1097/QAI.0000000000000790.

Ofotokun I, Na LH, Landovitz RJ, et al. Comparison of the metabolic effects of ritonavir- boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis, 2015 Jun 15, 60(12): 1842-1851. Available at http: //www.ncbi.nlm.nih.gov/pubmed/25767256.

Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S. ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet, 2014, 383(9936): 2222-31.doi: 10.1016/S0140-6736(14)60084-2

Molina J-M, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, de Oliveira CF, Brennan C on behalf of the FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV , 2015, 2: e127– 36. Published Online March 10, 2015 doi: 10.1016/S2352-3018(15)00027-2.

Eron JJ, Young B, Cooper DA. SWITCHMRK 1 and 2 investigators. Switch to a raltegravirbased regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicenter, double-blind, randomized controlled trials. Lancet, 2010, 375(9712): 396–407.

Martinez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavirboosted protease inhibitors in HIVinfected patients: the SPIRAL study. AIDS, 2010, 24(11): 1697- 1707. Available at http://www.ncbi.nlm.nih.gov/pubmed/20467288.

Naumann U et al. Real-life analysis of the German ‘WIP’ cohort. International Journal of STD & AIDS, 2016, 0(0) 1–9 The Author(s)

Stephan C. Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome — a meta-analysis of 12,370 patients in 21 clinical trials. 2013.

Letendre S et al. CROI, 2010, Abstract 172.

Maliakkal A et al. Reviewofthe Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy. J Acquir Immune Defic Syndr, 2016, 72: 153–161.

You J et al. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials. PLoS ONE, 2016, 11(8).

Eron JJ, Cooper DA, Steigbigel RT et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo- controlled trials. Lancet Infect Dis, 2013, 13(7): 587-596. Available at http://www.ncbi.nlm.nih.gov/pubmed/23664333.

Gotuzzo E, Markowitz M, Ratanasuwan W, Protocol 004 Study Team. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). J Acquir Immune Defic Syndr, 2012, 61(1): 73–77.

Tsai WJ, Lee SS, Tsai HC, et al. Rapid onset of rhabdomyolysis after switching to a raltegravir-based antiretroviral regimen. J Microbiol Immunol Infect, 2013, Epub April 20.

Croce F, Vitello P, Dalla Pria A, Riva A, Galli M, Antinori S. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. Int J STD AIDS, 2010, 21(11): 783–785.

Lee FJ, Amin J, Bloch M, Pett SL, Marriott D, Carr A. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr, 2013, 62(5): 525–533.

Raffi F, Pozniak AL, Wainberrg MA. Has the Time Come to Abandon Efavirenz for Fist-line Antiretroviral Trerapy? Journal of Antimicrobial Chemoterapy, 2014, 69(7): 1742-1747

Madeddu G, Menzaghi B, Ricci E, CISAI Group. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS, 2012, 26(18): 2412–2415.

Lepik KJ et al. Adverse drug reactions associated with integrase strand transfer inhibitors (INSTI) in clinical practice: Postmarketing experience with raltegravir, elvitegravir- cobicistat and dolutegravir. IAS 2015, Toronto. Poster abstract TuPEB258.

Giovanni Guaraldi et al. Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population. HIV/AIDS, CID, 2011: 53(1 December).

Keren Meir-Shafrir et al. Accelerated Aging in HIV Patients. RMMJ, 2012 October, 3(Issue 4): e0025.

Martinez E, Leyes P, Ros E. Effectiveness of lipid-lowering therapy in HIV patients. Curr Opin HIV AIDS, 2008, 3: 240–246.

Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, et al. (2012) Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS, 26: 475–481.

Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, et al. Hepatic safety prole of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother, 2010, 65: 543-547.

Кравченко А.В., Зимина В.Н., Попова А.А. и др., Эффективность и безопасность схемы терапии, включающей ралтегравир и комбинированный препарат с фиксированными дозами ламивудина и абакавира, у пациентов с туберкулезом и ВИЧ- инфекцией, получавших рифабутин. Тер. архив, 2014, 86(11): 34-41.

http: //www.hiv-druginteractions.org/

Cevik M et al. AswitchtoRaltegravir improves antiretroviral associated hepatotoxicity in individuals co-infected with HIV and hepatitis C. Journal of Infection, 2014 August, 69(Issue 2): 190–193.

Кравченко А.В., Куимова У.А., Канестри В.Г., Ганкина Н.Ю. Устойчивый вирусологический ответ при терапии хронического гепатита С у больных ВИЧ- инфекцией в зависимости от схемы антиретровирусной терапии. Материалы IV Ежегодного Всероссийского Конгресса по инфекционным болезням. Инфекционные болезни, 2012, 10(Приложение 1): 202-203.

Rx List. The Internet Drug Index for prescription drugs, medications and pillidentifier. http: //www.rxlist.com. Accessed August 16, 2015.

Nachega JB et al. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. HIV/AIDS, CID, 2014, 58(1 May): 1297-1307.

Покровский В.В., Юрин О.Г., Краченко А.В. и др. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧ-инфекцией. Клинический протокол. Эпидемиология и инфекционные болезни. Актуальные вопросы, 2016, 6(приложение): 1-72.

The authors declare that there are no conflicts of interest present.